{"id":"W4411027651","doi":"10.1200/jco.2025.43.17_suppl.lba1000","title":"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Human Epidermal Growth Factor Receptor 2; Internal medicine; Breast cancer; Oncology; Epidermal growth factor receptor; Cancer; Metastatic breast cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001324425,0.000861551,0.001215537,0.0003535699,0.0001789686,0.0006168907,0.0005705598,0.0009587489,0.003278207],"category_scores_gemma":[0.0008830946,0.0003103148,0.0009993912,0.000317665,0.0005199034,0.0007707495,0.0002103529,0.001891831,0.000499149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006731331,"about_ca_system_score_gemma":0.000621127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006520445,"about_ca_topic_score_gemma":0.002344945,"domain_scores_codex":[0.9997289,0.0001558518,0.00001597376,0.00003230426,0.00001977264,0.00004723524],"domain_scores_gemma":[0.9994748,0.0001856982,0.0001239763,0.00003197396,0.0000186891,0.0001648424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9407768,0.006447618,0.001223944,0.0004929058,0.0008210806,0.00005659307,0.00006639674,0.0008565444,0.007742464,0.0001416468,0.001326145,0.04004792],"study_design_scores_gemma":[0.6861032,0.2958199,0.009754166,0.0000755095,0.001264368,0.000193596,0.00006424244,0.001118248,0.002546934,0.0003868489,0.002643978,0.00002892173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901849,0.005465872,0.0003473481,0.0004016203,0.0002082764,0.0007029649,0.001069172,0.00007301763,0.00154687],"genre_scores_gemma":[0.9916773,0.003000434,0.0006407513,0.0006110757,0.0001605605,0.0006989917,0.001150353,0.00002572478,0.002034889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003278207,"threshold_uncertainty_score":0.01096666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03190532910319258,"score_gpt":0.4072173557020049,"score_spread":0.3753120265988124,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}